Cost effectiveness analysis in the treatment of acute cerebral thrombosis. Economic evaluation of antithrombin treatment using Argatroban.

DOI 1 Citations 21 References

Bibliographic Information

Other Title
  • 脳血栓症急性期治療におけるコスト・エフェクティブネス分析　　抗トロンビン薬アルガトロバンの医療経済性評価
  • Economic evaluation of antithrombin treatment using Argatroban
  • 抗トロンビン薬アルガトロバンの医療経済性評価

Search this article

Description

The cost effectiveness of conventional acute cerebral thrombosis treatment and conventional treatment plus antithrombin treatment using Argatroban was analyzed on the basis of double-bland test data comparing Argatroban (group A) with a placebo (group P). In this analysis, the longest admission term was 90 days, and effectiveness was defined as the decreased number of days of admission. Direct cost alone and direct indirect cost were examined retrospectively.<BR>The results obtained showed that the value anticipated for days remaining (90 days-days of admission: E) after discharge and cost (direct cost: DC; direct cost + indirect cost DC + IC) per patient averaged 56.2 days-DC 1, 035 thousand yen, and DC + IC 1, 558 thousand yen in group A, and 35.9 days-DC 1, 261 thousand yen, and DC + IC 1, 740 thousand yen in group P. The days of admission were fewer in group A than in group P by an average of 20.3 days; DC was estimated to have been reduced by 226 thousand yen and DC + IC by 182 thousand yen. The average cost per remaining day (C/E) was lower in group A than in group P for both DC and DC + IC, indicating that the Argatroban-supplemented treatment was more cost-effective than the placebo treatment. Treatment in which Argatroban is added to the treatment in group P (group A) is more effective and less costly than the treatment in group P, i. e. ΔC/ΔE is minus. Argatroban was thus verified to be useful both in terms of clinical effectiveness and from the economic viewpoint in medical treatment.

Journal

Citations (1)*help

See more

References(21)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top